Kinfo
Abivax SA Sponsored ADR logo

Abivax SA Sponsored ADR

ABVXNASDAQHealthcare·US · USD
$83.13
-0.48 (-0.57%)
Prices as of November 17, 2026 · live

Price

Key statistics

Valuation
Market cap7.32B USD
Enterprise value7.26B USD
Trailing P/E-17.32
Forward P/E-22.84
PEG ratio0.65
Price / sales1,642.43
Price / book16.99
Profitability
Gross margin0.00%
Operating margin-6270.37%
Profit margin0.00%
Return on assets-62.88%
Return on equity-252.35%
Income (TTM)
Revenue5.15M USD
Gross profit5.15M USD
EBITDA-321.43M USD
Net income-442.33M USD
Diluted EPS-$6.08
Rev. growth (YoY)-6.80%
Balance sheet
Total cash443.62M USD
Total debt1.34M USD
Debt / equity0.33
Current ratio5.97
Book value / share$5.16
Cash flow (TTM)
Operating cash flow-217.21M USD
Levered free cash flow-138.80M USD
Shares & price
Shares outstanding79.29M
Float65.34M
Held by institutions74.71%
Beta-0.33
50-day MA$94.85
200-day MA$112.57
52-week high$148.83
52-week low$69.81
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-09-21-0.86-1.69−96.51%2026-05-22-0.81-0.71+12.35%2026-03-23-1.04-1.18−13.46%2026-02-260.320.34+6.25%
About Abivax SA Sponsored ADR

Abivax SA Sponsored ADR is a biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to help stabilize the immune response in chronic inflammatory diseases. The company’s lead program centers on obefazimod, a clinical-stage candidate being studied for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. Abivax SA Sponsored ADR operates as a sponsored American Depositary Receipt representing the company’s ordinary shares, giving U.S. investors access to a France-based biopharmaceutical developer. Its current work is centered on clinical research, drug development, and advancing treatments aimed at complex immune-mediated conditions. Based in Paris, Abivax SA remains positioned within the global biotechnology market as a specialist in immunology-focused therapies and late-stage clinical development.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Marc M. P. de Garidel M.B.A.
Employees
98
Headquarters
Paris, France

Frequently asked questions about Abivax SA Sponsored ADR